secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2024-11-22T23:59:59+00:00
Accession:  0001654954-24-014793
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA Life Sciences regains Nasdaq minimum bid price compliance
---------------------------------------------------------------

- Received Nasdaq confirmation on Nov 21, 2024 that it meets Listing Rule 5550(a)(2).
- Avoids imminent delisting from Nasdaq; common stock (NDRA) continues trading.
- Acting CEO Alex Tokman says company will now focus on new transformational strategies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000165495424014793/0001654954-24-014793-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000165495424014793/endra_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-014793

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer